AMRI has entered into an agreement with the pharmaceutical group Ferrer and Accord Healthcare to jointly develop and manufacture an undisclosed complex parenteral drug product for registration and subsequent commercialization in the U.S. with the option to partner on additional drug products.

AMRI will work with Ferrer to develop and initially provide cGMP manufacturing and analytical support for the registration of the new product. Accord Healthcare will be responsible for advancing the product candidate through regulatory submission and commercialization.

“As one of the fastest growing generic companies in the United States, AMRI is very impressed with Accord’s performance and excited to be able to extend our deep scientific and product development expertise to help the company advance this product towards the market,” said William S. Marth, president and chief executive officer, AMRI. “Strategic partnerships, such as this agreement with Accord Healthcare, are just one example of how we can help biopharmaceutical companies enhance the value of their innovation and accelerate development and manufacturing, and at the same time we gain access to the benefits of the end market sales of the developed product when they become commercially available.”

Gerald Price, president, Accord Healthcare US and Canada, said, “AMRI brings unique capabilities and experience to drug development and manufacturing. We look forward to working with AMRI and Ferrer to leverage the companies’ complementary expertise and abilities to address the unique challenges involved in complex drug product development and manufacturing.” 

Visit AMRI at Interphex Booth 1228.